论文部分内容阅读
AIM:To assess long-term efficacy of initially successful endo-sponge assisted therapy.METHODS:Between 2006 and 2009,consecutive patients who had undergone primary successful endo-sponge treatment of anastomotic leakage following rectal cancer surgery were enrolled in the study.Patients were recruited from 6 surgical departments in Vienna.Clinical and oncologic outcomes were assessed through routine endoscopic and radiologic follow-up examination.RESULTS:Twenty patients(7 female,13 male)were included.The indications for endosponge treatment were anastomotic leakage(n=17)and insufficiency of a rectal stump after Hartmann’s procedure(n=3).All patients were primarily operated for rectal cancer.The overall mortality rate was 25%.The median followup duration was 17 mo(range 1.5-29.8 mo).Five patients(25%)developed a recurrent abscess.Median time between last day of endosponge therapy and occurrence of recurrent abscess was 255 d(range 21-733 d).One of these patients was treated by computed tomography-guided drainage and in 3 patients Hartmann’s procedure had to be performed.Two patients(10%)developed a local tumor recurrence and subsequently died.CONCLUSION:Despite successful primary outcome,patients who receive endo-sponge therapy should be closely monitored in the first 2 years,since recurrence might occur.
AIM: To assess long-term efficacy of initially successful endo-sponge assisted therapy. METHODS: Between 2006 and 2009, consecutive patients who had undergone primary successful endo-sponge treatment of anastomotic leakage following rectal cancer surgery were enrolled in the study. Pats were recruited from 6 surgical departments in Vienna. Clinical and oncologic outcomes were ordered through routine endoscopic and radiologic follow-up examination .RESULTS: Twenty patients (7 female, 13 male) were included.The indications for endosponge treatment were anastomotic leakage (n = 17 ) and insufficiency of a rectal stump after Hartmann’s procedure (n = 3). All patients were operated for rectal cancer. The overall mortality rate was 25%. The median follow-up was 17 months (range 1.5-29.8 mo) (25%) developed a recurrent abscess. Median time between last day of endosponge therapy and occurrence of recurrent abscess was 255 d (range 21-733 d). One of these patients was treated by computed t omography-guided drainage and in 3 patients Hartmann’s procedure had to be performed. Two patients (10%) developed a local tumor recurrence and succeeded died. CONCLUSION: Despite successful primary outcome, patients who receive endo-sponge therapy should be be monitored in the first 2 years, since recurrence might occur.